Friday 6 November 2026 Export AZN’s income statement to Excel — free account

AstraZeneca PLC

AZN Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.

Revenue: +6.70%
EPS: +22.5%
Free cash flow: +1.99%
Total debt: +1.75%

Quarter to September 2026, against a year earlier

187.20 1.81 −0.96%

Follow AZN

Alert me

Market cap: $289.8B
P/E: 26.3×
Fwd P/E: 24.5×
Dividend yield: 1.71%
F-score: 9/9
Altman Z: 3.52
Beneish M: −2.51
Dividend safety: 54/100

Overview

AstraZeneca PLC (AZN) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, AstraZeneca PLC (AZN) trades at a price to free cash flow of 45.8×. Over the past ten years it has ranged from 15.8× (December 2017) to 84.8× (November 2018); the current reading is higher than 90% of that period. That is above the Drug Manufacturers General industry median of 21.3× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/AZN/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="AstraZeneca PLC price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/AZN/metrics/price-to-free-cash-flow">AstraZeneca PLC (AZN) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	30.8×	13.94%
FY2024	27.1×	(8.08%)
FY2023	29.4×	11.00%
FY2022	26.5×	(29.58%)
FY2021	37.7×	(7.65%)
FY2020	40.8×	(18.64%)
FY2019	50.1×	87.30%
FY2018	26.8×	5.29%
FY2017	25.4×	21.07%
FY2016	21.0×	(58.11%)

Period	Price to free cash flow	Change
Sep 2026	39.5×	(15.76%)
Jun 2026	46.9×	21.99%
Mar 2026	38.5×	24.83%
Dec 2025	30.8×	28.83%
43 more quarters	Free account

Against its own ten years

Low 15.8× High 84.8×

Ten-year median 32.0×

Current reading's percentile 90

Company	Price to free cash flow
BMY Bristol Myers Squibb Company compare	13.9×
GILD Gilead Sciences, Inc. compare	15.1×
PFE Pfizer Inc. compare	15.5×
NVS Novartis AG compare	21.7×
MRK Merck & Co., Inc. compare	22.6×
NVO Novo Nordisk A/S compare	23.5×
ABBV AbbVie Inc. compare	27.1×
AMGN Amgen Inc. compare	27.3×
AZN AstraZeneca PLC	45.8×
Drug Manufacturers General industry median	21.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

AstraZeneca PLC (AZN) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on AZN

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on AZN

Stockrow Weekly